GSK's Flu Shot Just Beat the Old Guard. Now Comes the Hard Part.

This is the part of the story that should keep GSK executives up at night. History has a cautionary tale.

Another mRNA influenza program (not GSK's) ran a Phase 3 trial and found that while antibody levels looked great, the vaccine didn't meet noninferiority against its comparator on the primary efficacy endpoint. Translation: patients made plenty of antibodies, but that didn't translate into fewer people getting sick.

Think of it like a basketball player who dominates in practice but can't perform on game day. The skills are there on paper, but something doesn't click when it counts.

That precedent looms large over every mRNA flu program. GSK needs its Phase 3 to show not just that people's immune systems rev up more, but that fewer people actually catch the flu. Those are very different questions.

A Crowded, Complicated Race

GSK isn't the only company chasing the mRNA flu dream. The competitive landscape is intense, messy, and already littered with setbacks.

Moderna is the furthest ahead. Its lead candidate, mRNA-1010, produced antibody titers that were both noninferior and superior to licensed egg-based comparators in a Phase 3 trial of over 14,000 adults. But even Moderna hit a wall: in 2024, the FDA refused to review its application, saying the trial's comparator didn't match the best available U.S. standard of care. A brutal regulatory blow for what looked like solid data.

Pfizer has completed a Phase 3 study of its own quadrivalent mRNA flu vaccine in about 25,000 adults. But the company hasn't published full efficacy results yet, making it hard to judge where things stand.

Sanofi, meanwhile, has essentially left the building. The company discontinued its next-generation seasonal mRNA flu program and is now focusing only on pandemic flu preparedness. That's one fewer competitor at the table, but it also raises a question: if Sanofi looked at the economics and science and walked away, what did they see that others didn't?

The Design Decision That Could Make or Break GSK

GSK's candidate has an interesting design choice worth noting. It encodes both hemagglutinin (HA) and neuraminidase (NA), the two main proteins on the flu virus's surface. HA is what the virus uses to latch onto your cells; NA is what it uses to spread. Most traditional flu vaccines focus primarily on HA.

Targeting both proteins is like locking two doors instead of one. It could provide broader, more durable protection. Or it could introduce complexity that makes the vaccine harder to optimize. GSK is betting on the former.

The three-strain formulation (matching WHO-recommended strains) also means faster updates when new variants emerge, since mRNA vaccines can be redesigned from a genetic sequence without growing anything in eggs. That six-month egg-production bottleneck? Gone, at least in theory.

So Why Should You Care?

Flu kills between 290,000 and 650,000 people globally every year. And current vaccines are, frankly, mediocre; in bad years, effectiveness can dip below 30%. The entire flu vaccine industry is built on "good enough" because we never had a platform fast and flexible enough to do better.

mRNA could change that equation. COVID proved the platform works for a pandemic. Now the question is whether it works for a disease that shapeshifts every single year, in a market where the comparator isn't "no vaccine" but "a cheap, established vaccine that mostly does the job."

GSK's Phase 3 trial will be one of the most important readouts in the next two years for answering that question. The immune data look good. The design is clever. But Moderna's regulatory rejection and the failed noninferiority result from another program are reminders that this path is full of trap doors.

The mRNA flu race isn't a sprint. It's an obstacle course. And GSK just cleared the first wall.

Samsung Biologics Just Bet $1.8B That Peptides Are the Future

Samsung Biologics is going all-in on peptides with a $1.8 billion takeover bid for Swiss CDMO PolyPeptide Group. The deal is a direct play on insatiable GLP-1 manufacturing demand, and it signals that CDMO consolidation is only accelerating.